Acquisition Opportunity SAMDI Tech is now part of Charles River, offering an integrated access point to Charles River’s client base for HTS MS and label-free drug discovery solutions. Leverage the parent company’s relationships to cross-sell SAMDI’s rapid, quantitative assays as a complement to existing CRL offerings.

Small Team, Niche With a lean team of 2-10 employees, SAMDI Tech may benefit from scalable partnerships and channel programs. Target collaboration or co-sell arrangements with larger CROs and platform providers to expand capacity without proportional headcount growth.

HTS MS Leader Position SAMDI’s label-free high-throughput screening platform as a differentiator for faster go/no-go decisions. Highlight rapid data generation and quantitative SAMDI assays to customers seeking efficiency gains in early discovery and lead optimization.

Expansion Potential Recent acquisition by Charles River opens avenues to broaden geographic reach and client access. Propose joint marketing and case studies focused on scale-up screening programs and library expansion collaborations leveraging SAMDI’s technology.

Library Synergy SAMDI previously partnered to expand molecule libraries; explore co-development or licensing deals with Enamine-like partners and other database vendors to increase assay-ready compound inventories for customers pursuing diverse chemotypes.